688276 Changchun Bcht Biotechnology
- 38.55
- +0.02+0.05%
Changchun Bcht Biotechnology News
Huayuan Securities released a research report on April 25 stating that it gave Baike Biotech (688276.SH) a purchase rating. The main reasons for the rating include: 1) the burden of shingles disease is high, with more than 1.5 million new cases per year;
Huayuan Securities released a research report on April 25 stating that it gave Baike Biotech (688276.SH) a purchase rating. The main reasons for the rating include: 1) the burden of shingles disease is high, with more than 1.5 million new cases per year; 2) vaccine products have a good domestic competition pattern and huge market potential; 3) the two technical routes of recombination/attenuation each have advantages. In the context of the huge blue ocean market, we are optimistic about the future market space for the two products. (Mainichi Keizai Shimbun)
Baig Bio (688276): A healthy dose of chickenpox and shingles can be expected
Event: The company announced results for the first quarter of 2024. The first quarter of 2024 achieved operating income of 270 million yuan, a year-on-year increase of 50.64%; net profit to mother was 61 million yuan, an increase of 229.52% over the previous year; deducted from Africa
Chinese Drug Regulator Accepts BCHT Biotechnology's Marketing Application for Influenza Nasal Spray Vaccine
China's National Medical Products Administration accepted Changchun BCHT Biotechnology's (SHA:688276) marketing authorization application for its nasal spray vaccine against influenza, according to th
Southwest Securities released a research report on April 23 stating that it gave Baig Biotech (688276.SH) a purchase rating. The main reasons for the rating include: 1) continuous dosage of the shingles vaccine; 2) quarterly fluctuations in shingles vacci
Southwest Securities released a research report on April 23 stating that it gave Baig Biotech (688276.SH) a purchase rating. The main reasons for the rating include: 1) continuous dosage of the shingles vaccine; 2) quarterly fluctuations in shingles vaccine delivery, which can be expected throughout the year; 3) investing in mRNA technology platforms to effectively promote the development and layout of various mRNA vaccines and promote the company's diversification of technology and products. (Mainichi Keizai Shimbun)
Express News | Baike Biotech: The marketing license application for a live attenuated nasal spray influenza vaccine was accepted
Does Changchun BCHT Biotechnology (SHSE:688276) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it seems the smart m
Baike Biotech (688276): Shingles drives performance growth, influenza vaccine dosage upgrade is imminent
Baike Biotech Co., Ltd. announced that 2024Q1 achieved total operating revenue of 270 million yuan, a year-on-year increase of 50.64%; net profit attributable to owners of the parent company was 61 million yuan, an increase of 229.50% over the previous year; attributable to
Baig Biotech (688276): Shingles vaccine release drives performance growth
Incident: The company disclosed its 2024 quarterly report, achieving revenue of 270 million yuan, a year-on-year increase of 50.64%, and net profit to mother of 61 million yuan, an increase of 229.50% year-on-year, after deducting net profit of 60 million yuan.
Express News | Baike Biotech: Net profit increased 229.5% year-on-year in the first quarter
Baike Biotech (688276.SH) reported first-quarter results, net profit of 605.651 million yuan, an increase of 229.50% year-on-year
Baike Biotech (688276.SH) released its report for the first quarter of 2024. The company achieved operating income during the reporting period...
Express News | Baike Biotech: Net profit for the first quarter is expected to increase 199.22% year-on-year to 253.63%
Zhongtai Securities: Q1 results are about to be implemented, gradually focus on the pharmaceutical sector and individual stocks with improved Q2 performance
Zhongtai Securities said that at present, the overall market is still at a relative bottom. After experiencing a long-term correction, the pharmaceutical sector is also at multiple bottoms in terms of fundamentals, policies, and capital, and is firmly optimistic about the pharmaceutical sector market throughout the year.
Changchun BCHT Biotechnology (SHSE:688276) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Investors were disappointed with Changchun BCHT Biotechnology Co.'s (SHSE:688276) earnings, despite the strong profit numbers. We think that the market might be paying attention to some underlying fa
Baike Biotech (688276): Shingles vaccine strongly drives growth, innovative vaccines open up future space
Incident: The company released its 2023 annual report, achieving operating income of 1,825 million yuan, +70.30% year-on-year; net profit to mother of 501 million yuan, +175.98% year-on-year; net profit of non-return to mother of 493 million yuan, same
Baike Biotech (688276): Blisters boost performance and expect continued growth
Incident The company released its 2023 annual report. In 2023, it achieved revenue of 1,825 billion yuan, a year-on-year increase of 70.30%; net profit to mother was 501 million yuan, an increase of 175.98%; net profit not attributable to mother4
Baike Biotech: Liquid nasal spray influenza vaccine products will soon apply for marketing approval
Glonghui, March 22 | Baike Biotech said on an interactive platform that the applicable age for clinical research on the company's liquid nasal spray influenza vaccine is 3-59 years old, and the product will soon apply for marketing approval.
Baike Biotech (688276): The contribution of shingles to elasticity continues to advance in the research pipeline
Investment highlights: Event: The company released its 2023 annual report. In 2023, the company achieved operating income of 1,825 million yuan (+70.30%) and realized net profit of 501 million yuan (+175.98%) to mother, achieved
Baig Biotech (688276): Performance is in line with expectations, rapid release of domestically produced shingles vaccine
Incident: The company disclosed its 2023 annual report, achieving revenue of 1,825 billion yuan, a year-on-year increase of 70.30%; net profit to mother of 501 million yuan, an increase of 175.98%; net profit of non-return to mother of 493 million yuan.
Changchun BCHT Biotechnology's 2023 Profit Soars 176% as Revenue Jumps 70%
Changchun BCHT Biotechnology's (SHA:688276) attributable profit surged 175.98% to 501 million yuan in 2023 from 181.5.million yuan in 2022, according to a Wednesday filing with the Shanghai bourse. Ea
Express News | The Social Security Fund appeared as the top ten tradable shareholders with 7 individual shares
Analysis
Price Target
No Data
